ChiCTR2000031276 版本V1.3 版本创建时间2020/03/30 00:27:35 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000031276 

最近更新日期:

Date of Last Refreshed on:

2020-03-26 21:20:24 

注册时间:

Date of Registration:

2020-03-26 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

应用人工智能算法自动提取放疗鼻咽癌患者危及器官轮廓的可行性分析

Public title:

Feasibility analysis of automatic segmentation of organs at risk for patients with nasopharyngeal carcinoma receiving radiotherapy using artificial intelligence algorithms

注册题目简写:

English Acronym:

研究课题的正式科学名称:

应用人工智能算法自动提取放疗鼻咽癌患者危及器官轮廓的可行性分析

Scientific title:

Feasibility analysis of automatic segmentation of organs at risk for patients with nasopharyngeal carcinoma receiving radiotherapy using artificial intelligence algorithms

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

宋威 

研究负责人:

宋威 

Applicant:

Song Wei 

Study leader:

Song Wei 

申请注册联系人电话:

Applicant telephone:

+86 13952056710

研究负责人电话:

Study leader's telephone:

+86 13952056710

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

swjacke@hotmail.com

研究负责人电子邮件:

Study leader's E-mail:

swjacke@hotmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国江苏省南京市汉中路155号南院Q211

研究负责人通讯地址:

中国江苏省南京市汉中路155号南院Q211

Applicant address:

Room Q211, South Hospital of Jiangsu Hospital of traditional Chinese Medicine, 155 Hanzhong Road, Nanjing, Jiangsu, China

Study leader's address:

Room Q211, South Hospital of Jiangsu Hospital of traditional Chinese Medicine, 155 Hanzhong Road, Nanjing, Jiangsu, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

江苏省中医院

Applicant's institution:

Jiangsu Province Hospital of Chinese Medicine

研究负责人所在单位:

江苏省中医院

Affiliation of the Leader:

Jiangsu Province Hospital of Chinese Medicine

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2019NL-151-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

南京中医药大学附属医院(江苏省中医院)伦理委员会

Name of the ethic committee:

Institutional Review Board of Human Research in Affiliated Hospital of Nanjing University of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2019-11-14 00:00:00

伦理委员会联系人:

吴静

Contact Name of the ethic committee:

Wu Jing

伦理委员会联系地址:

中国江苏省南京市汉中路155号

Contact Address of the ethic committee:

155 Hanzhong Road, Nanjing, Jiangsu, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

江苏省中医院

Primary sponsor:

Jiangsu Province Hospital of Chinese Medicine

研究实施负责(组长)单位地址:

中国江苏省南京市汉中路155号

Primary sponsor's address:

155 Hanzhong Road, Nanjing, Jiangsu, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

南京

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

江苏省中医院

具体地址:

汉中路155号

Institution
hospital:

Jiangsu Province Hospital of Chinese Medicine

Address:

155 Hanzhong Road

经费或物资来源:

江苏省中医院

Source(s) of funding:

Jiangsu Province Hospital of Chinese Medicine

Target disease:

Nasopharyngeal carcinoma

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

评估人工智能深度学习算法自动勾画鼻咽癌患者危及器官轮廓勾画准确性。  

Objectives of Study:

To evaluate the accuracy of automatic delineation of organs at risk for patients with nasopharyngeal carcinoma receiving raditherapy using the artificial intelligence deep learning algorithm.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 符合鼻咽癌诊断标准在我院已接受过放疗的鼻咽癌患者。
2. 年龄在18~90岁之间,性别不限。
3. 患者采用仰卧位定位,双手置于身体两侧。
4. 患者CT扫描范围包括从头顶至气管分叉水平,扫描层厚为小于等于3 mm。
5. 知情同意,志愿受试。获得知情同意书过程应符合GCP规定。

Inclusion criteria

1. Patients with nasopharyngeal carcinoma and have received radiotherapy in our hospital.
2. Patients with ages ranging from 18 to 90 regardless of gender.
3. Patients are positioned in supine position with hands at their sides.
4. The CT scan range of the patient is from the top of the head to the level of bronchial bifurcation, and the thickness of the scan layer was less than or equal to 3 mm.
5. Informed consent and volunteer patients. The process of obtaining the informed consent shall comply with the GCP regulations.

排除标准:

1. 妊娠期、哺乳期妇女。
2. 由于智力或行为障碍不能给予充分知情同意者。

Exclusion criteria:

1. Patients who are pregnant and lactating women.
2. Patients who are unable to give full informed consent due to intellectual or behavioral disorders.

研究实施时间:

Study execute time:

From 2019-11-14 00:00:00 To 2021-11-14 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-04-15 00:00:00 To 2021-04-15 00:00:00  

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

医师人工勾画危及器官轮廓

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

Mannual segmentation of organs at risk by doctors.

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

人工智能模型自动勾画危及器官轮廓

Index test:

Automatic segmentation of organs at risk using artificial intelligence algorithms

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

放疗鼻咽癌患者

例数:

Sample size:

100

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

Patients with nasopharyngeal carcinoma and have received radiotherapy.

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

例数:

Sample size:

0

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China 

Province:

Jiangsu 

City:

 

单位(医院):

江苏省中医院 

单位级别:

三甲医院 

Institution
hospital:

Jiangsu Province Hospital of Chinese Medicine

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

相似性系数

指标类型:

主要指标

Outcome:

Dice Similarity Coefficient

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 90 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不涉及随机方法,本研究设计基于一种非随机对照试验方法,即自身前后对照试验方法,对所有样本分别执行人工智能模型自动勾画危及器官轮廓和医师人工勾画危及器官轮廓。

Randomization Procedure (please state who generates the random number sequence and by what method):

Not applicable. This study is designed based on a non-randomized controlled trial, ie.self-controlled study. Organs at risk for all of the samples will be contoured using automatic and mannual segmentation,respectively.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

未说明

Blinding:

Not stated

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2022年3月31日前。向研究者联系索取swjacke@hotmail.com。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Before December 31, 2021, contact the researcher for access to data, swjacke@hotmail.com.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

(一)数据记录 1.研究病历是临床试验受试者的源文件(source document),应保存于医院。研究病历是门诊受试者的病历资料,与住院病历共同组成住院受试者的病历资料。 2. 研究病历记录要求:①研究者必须在诊治受试者同时书写研究病历,保证数据记录及时、完整、准确、真实。②研究病历做任何有证据的更正时只能划线,旁注改后的数据,由研究者签名并注明日期,不得擦涂、覆盖原始记录。③门诊受试者的原始化验单粘贴在研究病历上,住院受试者的原始化验单粘贴在住院病历上。门诊与住院受试者的化验结果均需填写至研究病历的“理化检查结果报告表”。 (二)数据报告 研究病历 (三)数据监查 研究者审核每份研究病历。 (四)数据核查 1. 建立数据库。 2. 数值范围和逻辑检查,如有疑问,填写疑问清单(query list),由研究者对疑问清单中的问题进行解答。完成数据核查报告后,锁定数据库。 3. 应保存质量控制的有关文件,如数据一致性检查、数值范围和逻辑检查的原始记录、盲态审核时的原始记录、研究者之间交流的疑问记录等。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

1. Data records (1) The study medical record is the source document of the subjects in the clinical trial and should be kept in the hospital.The study medical records are the medical records of outpatient subjects, which together with the inpatient medical records constitute the medical records of inpatient subjects. (2) Requirements for research medical records: the researcher must write the medical records at the same time as the treatment of the subjects, so as to ensure that the data records are timely, complete, accurate and true. when making any corrections to the medical records, the author should only underline the data with sidenote changes where should be signed and dated by the researcher, and the original records should not be erased or overwritten.The original laboratory tests of outpatient subjects are pasted on the study medical records, and the original laboratory tests of inpatient subjects are pasted on the medical records.The test results of both outpatient and inpatient subjects should be filled in the "physical and chemical examination results report form" in the study medical records. 2. Data report The medical records 3. Data monitoring The researchers reviewed each study's medical records. 4. Data verification (1) Build a database. (2) Check the numerical range and logic. If in doubt, fill in the query list, and the researcher will answer the questions in the query list. After completing the data verification report, lock the database. (3) Relevant documents of quality control shall be kept, such as original records of data consistency check, numerical range and logical check, original records of blind state audit, and records of questions exchanged between researchers, etc.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-03-26 20:08:30